Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation.

Summary

The purpose of this study is to compare the preference of Calcichew D3 500/400 (containing 500 mg calcium and 400 IU of vitamin D) with Adcal-D3 600/400 (containing 600 mg of calcium and 400 IU of vitamin D) in Test Group 1, and to compare Calcichew D3 500/800 (containing 500 mg calcium and 800 IU vitamin D) with Kalcipos-D 500/800 (containing 500 mg of calcium and 800 IU of vitamin D) in Test Group 2.

Timeline

Start

2015-06

Primary completion

2015-08

Completion

2015-08

Outcome

Met primary endpoint

paper Calcichew 500/400 (77.6%) over Adcal-D3 was 3.46 ([95% CI 2.24, 5.36], p < 0.001) in Group 1 PMID 27322906 ↗

paper Calcichew D3 500/800 (63.2%) over Kalcipos-D was 1.72 ([1.19, 2.47], p = 0.004) in Group 2 PMID 27322906 ↗

Publications

• Thomasius F, Keung Nip T, Ivan P. Phase IV randomized preference study in patients eligible for calcium and vitamin D supplementation. Curr Med Res Opin. 2016 Oct;32(10):1623-1631. doi: 10.1080/03007995.2016.1202817. Epub 2016 Jun 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adcal-D3	Unknown	400 iu	Oral
Subject	Adcal-D3	Unknown	600 mg	Oral
Subject	Calcichew D3	Unknown	400 iu	—
Subject	Calcichew D3	Unknown	500 mg	—
Subject	Calcichew D3	Unknown	800 iu	—
Subject	Kalcipos-D	Unknown	500 mg	Oral
Subject	Kalcipos-D	Unknown	800 iu	Oral

Indications